References
Zwaan CM, Reinhardt D, Jurgens H, Huismans DR, Hahlen K, Smith OP et al. Gemtuzumab ozogamicin in pediatric CD33-positive acute lymphoblastic leukemia: first clinical experiences and relation with cellular sensitivity to single agent calicheamicin. Leukemia 2003; 17: 468–470.
Balduzzi A, Rossi V, Corral L, Bonanomi S, Longoni D, Rovelli A et al. Molecular remission induced by gemtuzumab ozogamicin associated with donor lymphocyte infusions in t(4;11) acute lymphoblastic leukemia relapsed after transplantation. Leukemia 2003; 17: 2247–2248.
Cotter M, Rooney S, O'Marcaigh A, Smith OP . Successful use of gemtuzumab ozogamicin in a child with relapsed CD33-positive acute lymphoblastic leukaemia. Br J Haematol 2003; 122: 687–688.
Uckun FM, Sather HN, Gaynon PS, Arthur DC, Trigg ME, Tubergen DG et al. Clinical features and treatment outcome of children with myeloid antigen positive acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 1997; 90: 28–35.
Putti MC, Rondelli R, Cocito MG, Arico M, Sainati L, Conter V et al. Expression of myeloid markers lacks prognostic impact in children treated for acute lymphoblastic leukemia: Italian experience in AIEOP-ALL 88-91 studies. Blood 1998; 92: 795–801.
Czuczman MS, Dodge RK, Stewart CC, Frankel SR, Davey FR, Powell BL et al. Value of immunophenotype in intensively treated adult acute lymphoblastic leukemia: cancer and leukemia Group B study 8364. Blood 1999; 93: 3931–3939.
Wiersma SR, Ortega J, Sobel E, Weinberg KI . Clinical importance of myeloid-antigen expression in acute lymphoblastic leukemia of childhood. N Engl J Med 1991; 324: 800–808.
Fink FM, Koller U, Mayer H, Haas OA, Grumayer-Panzer ER, Urban C et al. Prognostic significance of myeloid-associated antigen expression on blast cells in children with acute lymphoblastic leukemia. The Austrian Pediatric Oncology Group. Med Pediatr Oncol 1993; 21: 340–346.
Sobol RE, Mick R, Royston I, Davey FR, Ellison RR, Newman R et al. Clinical importance of myeloid antigen expression in adult acute lymphoblastic leukemia. N Engl J Med 1987; 316: 1111–1117.
Pui CH, Behm FG, Singh B, Rivera GK, Schell MJ, Roberts WM et al. Myeloid-associated antigen expression lacks prognostic value in childhood acute lymphoblastic leukemia treated with intensive multiagent chemotherapy. Blood 1990; 75: 198–202.
Den Boer ML, Kapaun P, Pieters R, Kazemier KM, Janka-Schaub GE, Veerman AJ . Myeloid antigen co-expression in childhood acute lymphoblastic leukaemia: relationship with in vitro drug resistance. Br J Haematol 1999; 105: 876–882.
Firat H, Favier R, Adam M, Leverger G, Landman-Parker J, Cayre Y et al. Determination of myeloid antigen expression on childhood acute lymphoblastic leukaemia cells: discrepancies using different monoclonal antibody clones. Leuk Lymphoma 2001; 42: 675–682.
van Wering ER, Beishuizen A, Roeffen ET, van der Linden-Schrever BE, Verhoeven MA, Hahlen K et al. Immunophenotypic changes between diagnosis and relapse in childhood acute lymphoblastic leukemia. Leukemia 1995; 9: 1523–1533.
Kalina T, Vaskova M, Mejstrikova E, Madzo J, Trka J, Stary J et al. Myeloid antigens in childhood lymphoblastic leukemia: clinical data point to regulation of CD66c distinct from other myeloid antigens. BMC Cancer 2005 (in press).
van der Velden VH, Boeckx N, Jedema I, te Marvelde JG, Hoogeveen PG, Boogaerts M et al. High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients. Leukemia 2004; 18: 983–988.
Acknowledgements
We thank J Ridoskova, K Pospisilova, L Gondorcinova, P Hanusova and N Holosova for technical assistance. Collaboration of Czech Pediatric Hematology (CPH) centers (data manager A Vrzalova, leaders: B Blazek (Ostrava), Z Cerna (Plzen), Y Jabali (Ceske Budejovice), V Mihal (Olomouc), D Prochazkova (Usti nad Labem), J Sterba (Brno), J Hak and K Tousovska (Hradec Kralove)) and statistical help of P. Martinkova is appreciated. The work was supported by grants: GA UK 80 and 65 (2004), MZ CR 7430-3 and MSM0021620813.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information
Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu).
Supplementary information
Rights and permissions
About this article
Cite this article
Mejstříková, E., Kalina, T., Trka, J. et al. Correlation of CD33 with poorer prognosis in childhood ALL implicates a potential of anti-CD33 frontline therapy. Leukemia 19, 1092–1094 (2005). https://doi.org/10.1038/sj.leu.2403737
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2403737
- Springer Nature Limited
This article is cited by
-
The intriguing roles of Siglec family members in the tumor microenvironment
Biomarker Research (2022)
-
CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL
Cancer Immunology, Immunotherapy (2021)
-
Using the Lessons Learned From the Clinic to Improve the Preclinical Development of Antibody Drug Conjugates
Pharmaceutical Research (2015)
-
CD2-positive B-cell precursor acute lymphoblastic leukemia with an early switch to the monocytic lineage
Leukemia (2014)
-
Pediatric Relapsed or Refractory Leukemia: New Pharmacotherapeutic Developments and Future Directions
Drugs (2013)